{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu PC"],"funding":["CAMS Innovation Fund for Medical Sciences","\"Xing Yao\" Leading Scholars of China Pharmaceutical University","National Natural Science Foundation of China","Medical Innovation and Development Project of Lanzhou University","Innovation and Entrepreneurship (Shuangchuang) Program of Jiangsu Province","Changsha \"Jie Bang Gua Shuai\" Major Science and Technology Programs","Natural Science Foundation of Jiangsu Province"],"pagination":["e01602"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12786276"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(2)"],"pubmed_abstract":["CD47/signal-regulatory protein α (SIRPα) signaling enables malignant cells to evade macrophage-mediated phagocytosis, offering a promising strategy for cancer therapy via immune checkpoint blockade. However, this strategy is widely debated due to several safety risks revealed by clinical studies, including anemia. Here, a CD47-SIRPα immune checkpoint treatment is investigated that mitigates anemic side effects by selectively interfering with the costabilization of CD47 and integrin αvβ3 on cancer cell surfaces, a phenomenon absent in erythrocytes. Multiplexed immunofluorescence analysis of 119 clinical breast cancer tissues reveals this costabilization. The engineered peptide PSFL-NK13 effectively disrupts this costabilization, which enhances macrophage phagocytosis and delays tumor growth"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface."],"pmcid":["PMC12786276"],"funding_grant_id":["JSSCTD202350","2019-I2M-5-074","KQ2301004","BK20202002","YB M-05-02","lzuyxcx-2022-156","32371289"],"pubmed_authors":["Hao CY","Qiao YF","Wang DP","Yu PC","Dong WZ","Yue CX","Fan YZ","Zhang X","Zhan Q","Yao JB","Liu D","Cao P","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface.","description":"CD47/signal-regulatory protein α (SIRPα) signaling enables malignant cells to evade macrophage-mediated phagocytosis, offering a promising strategy for cancer therapy via immune checkpoint blockade. However, this strategy is widely debated due to several safety risks revealed by clinical studies, including anemia. Here, a CD47-SIRPα immune checkpoint treatment is investigated that mitigates anemic side effects by selectively interfering with the costabilization of CD47 and integrin αvβ3 on cancer cell surfaces, a phenomenon absent in erythrocytes. Multiplexed immunofluorescence analysis of 119 clinical breast cancer tissues reveals this costabilization. The engineered peptide PSFL-NK13 effectively disrupts this costabilization, which enhances macrophage phagocytosis and delays tumor growth","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T11:44:55.795Z","creation":"2026-05-30T03:07:24.534Z"},"accession":"S-EPMC12786276","cross_references":{"pubmed":["41168993"],"doi":["10.1002/advs.202501602"]}}